# Bioequivalence Study of Sorafenib Tablet and Nexavar

> **NCT02599337** · PHASE1 · COMPLETED · sponsor: **Yabao Pharmaceutical Group** · enrollment: 36 (actual)

## Conditions studied

- Fasting

## Interventions

- **DRUG:** Nexavar
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02599337
- **Lead sponsor:** Yabao Pharmaceutical Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2015-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02599337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02599337, "Bioequivalence Study of Sorafenib Tablet and Nexavar". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02599337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*